Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

At present, six groups of chronic pulmonary hypertension (PH) are described. Among these,
group 1 (and 1′) comprises a group of diverse diseases termed pulmonary arterial …

Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …

Background—The plexiform lesion is the hallmark of severe pulmonary arterial
hypertension. However, its genesis and hemodynamic effects are largely unknown because …

Vascular walls change their dimension and mechanical properties in response to injury such
as balloon angioplasty and endovascular stent implantation. Placement of bare metal stents …

Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial
obstruction increases pulmonary vascular resistance, which leads to right ventricular (RV) …

Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with
pulmonary artery hypertension (PAH). Several animal models of PAH cite the potential role …

Recent clinical and experimental studies are redefining the cellular and molecular bases of
pulmonary arterial hypertension (PAH). The genetic abnormalities first identified in …

Background—Pulmonary arterial hypertension (PAH) is associated with sustained
inflammation known to promote DNA damage. Despite these unfavorable environmental …

Recent investigations have suggested that it might be possible to reverse the pathology of
pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal …